title: Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe.
abstract: Survival rates of patients with either early and advanced stage non-small-cell lung cancer (NSCLC) have improved with newer systemic therapy and radiation techniques, including combination regimens, targeted therapies, and immunotherapies. The cancer cooperative groups have historically played a critical role in the advancement of NSCLC therapy. Annually, representatives from cooperative groups worldwide convene at the International Lung Cancer Congress (ILCC). In summer 2015, the ILCC reached its 16th anniversary. This article highlights the NSCLC studies presented by participating groups in 2015.
authors.affiliation: Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
authors.forename: Ameen Abdulla
authors.initials: AA
authors.lastname: Salahudeen
authors.affiliation: Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
authors.forename: Manali I
authors.initials: MI
authors.lastname: Patel
authors.affiliation: Thoracic Oncology, Faculty of Medicine, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL), University of Amsterdam (AMC-UvA), Amsterdam, Netherlands.
authors.forename: Paul
authors.initials: P
authors.lastname: Baas
authors.affiliation: Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Curran
authors.affiliation: S. Lee Kling Center for Proton Therapy, School of Medicine, Washington University in St. Louis, St. Louis, MO.
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Bradley
authors.affiliation: Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, Davis, CA.
authors.forename: David R
authors.initials: DR
authors.lastname: Gandara
authors.affiliation: Division of Oncology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
authors.forename: Glenwood D
authors.initials: GD
authors.lastname: Goss
authors.affiliation: Department of Clinical Oncology, Chinese Medical University of Hong Kong Shatin, New Territories, Hong Kong.
authors.forename: Tony S
authors.initials: TS
authors.lastname: Mok
authors.affiliation: Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
authors.forename: Suresh S
authors.initials: SS
authors.lastname: Ramalingam
authors.affiliation: Department of Medicine, University of Chicago School of Medicine, Chicago, IL.
authors.forename: Everett E
authors.initials: EE
authors.lastname: Vokes
authors.affiliation: Clinical Investigational Branch, CTEP/DCTD/NCI/NIH, Rockville, MD.
authors.forename: Shakun M
authors.initials: SM
authors.lastname: Malik
authors.affiliation: Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA. Electronic address: hwakelee@stanford.edu.
authors.forename: Heather A
authors.initials: HA
authors.lastname: Wakelee
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D007391:International Cooperation; D011379:Prognosis; D013899:Thoracic Neoplasms / Q000628:therapy*
keywords: Cooperative group; Mesothelioma; NCTN; NSCLC; SCLC